Clinical Trials Browser

Phase 2 × Inflammatory Breast Neoplasms × Nivolumab × Clear all

NCT02892734 2020-07-16

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Phase 2 Terminated

3 enrolled 11 charts

Breast Neoplasms, Inflammatory Breast Neoplasms